Icon
+91 94997 68112
Login Register

Clobex - (SPRAY, TOPICAL 0.05%)

Clobetasol Propionate Galderma
SPRAY, TOPICAL 0.05%
Less Than $1000 mn
Less Than 5
Less Than 5
None None
More Than 5
More Than 5
Indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.
Yes
******* ** *** ***** ** **** **** ** **** ****** ***** *** ****** '*** ******** ** *** **, **** *** *** ************ *********. ***** ********* ******* * ********** **** ******* ***** ***** ******* ******** ******** & ******** *** *******. ***** ******* *** ***** * **** ** **** **** ****** ** ******* & *** ************ *********. ******* ******* ******** ******* **** *********** ******* ** ********* *** **** ****** ** *** ****** *** *** *******. **** ***** ***** ***** **** ** **** *** **** ****** *** *** ************. ** **** **** **** ***** *** **** **, ********** *** ******* **** ***** ***** *** ***** ** ********** *** *** *****.
Clobex Patent 1
******* *******
***** *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** **** ******* ******** ******** ** *** *, ****
***** ** \ ** *** **, **** ******* ******** ******** ** *** **, ****
  1. ***, **** : ******* ******** ******** ***** *** ****** ****** **** *.**% ******* ***** ** ****** *** ****** *******.
  2. ***, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  3. ***, **** : ******* ******** ******** ***** *** ****** ****** **** *.**% ******* ***** ** ****** *** ****** *******.
  4. ***, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  5. ***** *, **** : ******** & ******* ******* * **********. **** ********** *** ********* ***** *** ***** ****** ********* ****** ** *******'* *****.
  6. **** **, **** : ******* ******** ******** *** ******** *** *******.
  7. **** **, **** : ******* ******** *******.
  8. *** **, **** : ******** ***** * **** ******* ***** ** ***** ***** **** ** **** ****** '***.
  9. *** **, **** : ********** *** ********* **** ***** ***** *** ***** ** ********** *** *** *****.

Clobex - (Shampoo, topical, 0.05%)

Clobetasol Propionate Galderma
Shampoo, topical, 0.05%
Less Than $1000 mn
Less Than 5
More Than 5
More Than 5
 None
More Than 5
More Than 5
Used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis
Yes
******* ** *** ***** ** **** **** ** **** ******* '*** & '*** ******** ** *** **, **** & *** *, **** ************ & *** ************ *********. ******* ******* ******* * ********** **** ********. ******* *** ** ***** ************** ** ********** *************** ******** ******* **** ** ****** ** ******* ********* ******** ****** *** ********** ** ******. ******* ******* *** ******* ** ******** **** ***** *** *** ******* *** *** **** *********** ***** ******* ****. ** ***** ** ** **** ******* *** *** *** ******** *** *******.
Clobex Patent 1 Patent 2
******* ******* *******
******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** *, **** ******* ******** ******** ** *** *, ****
******* ** \ ** ***, **** ******* ******** ******** ** *** **, ****
  1. *** *, **** : ******* ***** * **** ** **** ****** *** ****** ******* & *******. ******** ***** * **** ******* ******* ** ******** ***** ** ******** ******** ** *****, **** ***** ********.
  2. *** *, **** : ********** **** ******* *** *******.
  3. ****, **** : ******* ******** ******** ***** *** **** ** ****** **** *.**% ******* *** ******* & *******.
  4. ***, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  5. **** *, **** : ******* ******** ********.
  6. *** *, **** : ********** **** ******* *** *******.

Clobex - (0.05% lotion, Topical)

Clobetasol Propionate Galderma
0.05% lotion, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
Less Than 5
super-high potent corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses only in patients 18 years of age or older
Yes
******* ** *** ***** ** **** **** ** **** ****** ****** *** ****** '*** (******** ** **** **, ****) ************ *** ********* ** ********. ******* ********** **** ******* *** ********* (******** * **********). ******* ******** ** ******** *** ******** ****** ******* *** ****** ** ****. ***** *** (****) *** ********* ****** **** ***** * **** ** **** ****** *** **** ****** (** *** *******) *** **** ************ *********. ********** *** ******* **** ***** *** ********* ** **** ********* ** *** ***** ** ***** **** *** ********* ******** *** ****** ****** ** ****,
Clobex Patent 1
******* *******
*** (****) *******
******** (*** ****) *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** **** ******* ******** ******** ** *** *, ****
*** (****) ** \ ** *** **** ******* ******** ******** ** *** *, ****
******** (*** ****) ** \ ** *** *, **** ******* ******** ******** ** *** **, ****
  1. ***, **** : ******* ******** ******** ***** *** **** ** **** *.**% ****** *** ****** *******.
  2. ****, **** : ******** ***** * **** ******* ******* ** ******** ******** ***** ** *****.
  3. ***, **** : ******** *********** ********* *** **** ******* ******* & ******* ******** ********.
  4. ***, **** : **** ******** ******** ***** *** **** ** **** *.**% ****** *** ****** *******.
  5. ***, **** : ******** ***** * **** ******* **** ** ******** ******** ***** ** *****.
  6. **** *, **** : ******* ******** ********.
  7. *** **, **** : ********** *** ********* **** **** ***** *** ***** ** ********* *** *** *****. ** ****** **** ** **** ****** *** **** ***** *******.
  8. *** *, **** : ******** ***** * **** ******* ******** (*** ****) ** ******** ***** ** ******** ******** ** ***** ****** ******** ** *** ******* ***** **** ** **** ****** '***.
  9. *** **, **** : ********** *** ********* **** ******** (*** ****) ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.